The inhibition of glandular kallikrein by peptide analog antagonists of bradykinin.
Bradykinin sequence analog receptor antagonists exhibit at their carboxyl termini features which contribute to the affinity of peptide inhibitors of glandular kallikreins. These features include a preference for L-Arg over L-Lys at position P1 and bulky D-amino acids at P3. There is minimal steric restriction at P2. Three representative receptor antagonists were examined for their capacity to inhibit the amidolytic activity of human urinary kallikrein (HUK). The Ki values for B4307 (DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DPhe-Thi-Arg), B4308 (Lys-Lys-Arg-Hyp-Hyp-Gly-Thi-Ser-DPhe-Thi-Arg), and B3852 (Arg-Pro-Hyp-Gly-Phe-Ser-DPhe-Phe-Arg) are 0.5, 0.3 and 2.5 microM, respectively. B4308 and B3852 were also shown to inhibit rat urinary kallikrein with Ki's of 1.0 and 5.5 microM. In the estrous rat uterus assay, 0.4 to 1.6 microM quantities of B4308 gave 5 to 10 times as much inhibition of contractile activity when added at the beginning of the incubation of HUK with human low molecular weight kininogen than when added upon addition of the mixture to the organ bath. These antagonists may inhibit the kallikrein-kinin system not only by blocking the binding of kinins to their receptor(s) but also by inhibiting the release of kinins from kininogens.
Spragg
J
J
Department of Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA.
Vavrek
R J
RJ
Stewart
J M
JM
D001920:Bradykinin / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors* / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000378:metabolism*; D006801:Humans; D007610:Kallikreins / Q000378:metabolism*; D007700:Kinetics
D004791:Enzyme Inhibitors; D007610:Kallikreins; D001920:Bradykinin